Mizuho analyst Eric Criscuolo raised his price target for Thermo Fisher (TMO) to $170 from $166 following the company's acquisition of FEI Company (FEIC). The analyst notes that the deal is a bit outside of Thermo Fisher's recent acquisitions but he still sees the strategic rationale. Criscuolo believes FEI should fit well within Thermo Fisher's organization, while enhancing an already "strong" value proposition to the biopharma market. Even though the analyst is not surprised that Thermo Fisher keeps consolidating the life science tools market, he expects its M&A activity to pause a bit near-term. Mizuho has a Buy rating on Thermo Fisher's shares.

Deutsche Bank raised the firm's price target on Thermo Fisher to $610 from $600 and keeps a Buy rating on the shares post the Q1 report. The analyst says a solid operational performance drove a strong start to 2024.

Barclays analyst Luke Sergott raised the firm's price target on Thermo Fisher to $615 from $590 and keeps an Equal Weight rating on the shares. The company reported a beat across the board, says the analyst, who sees the business stabilizing.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here